{
  "id": 12159220,
  "title": "Ionis Pharmaceuticals stock hits 52-week low at 42.96 USD",
  "url": "https://urgent.news/2026/10/05/ionis-pharmaceuticals-stock-hits-52-week-low-at-42-96-usd",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-05T13:41:13.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/ionis-pharmaceuticals-stock-hits-52week-low-at-4296-usd-93CH-4932370"
  },
  "original_language": "en",
  "account": "Ionis Pharmaceuticals stock plummeted to its 52-week low of $42.96, currently trading at $42.82, far below its 52-week high of $86.74. In the past year, the company's stock has plummeted by 37.66%, with a recent decline accelerating at 45% year-to-date and 42% over the last six months. An InvestingPro tip highlights the RSI indicates the stock is in oversold territory, while the Fair Value analysis suggests shares may be overvalued at current levels. This sharp decline underscores ongoing challenges and investor concerns affecting the company's market performance. Ionis Pharmaceuticals finds itself at a critical juncture as it strives to regain investor confidence and stabilize its stock value amid these trying times. While the company has reported positive clinical trial results for its drugs sefaxersen and ulefnersen, analysts maintain varied outlooks on Ionis's future prospects.",
  "summary": null,
  "key_points": [
    "Ionis Pharmaceuticals stock reaches 52-week low of $42.96",
    "Stock price down 37.66% over the past year",
    "Oversold RSI suggests potential overvaluation at current levels"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}